Hematologic Neoplasms Clinical Trial
Official title:
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation
Graft-versus-host-disease (GVHD) is common complication of hematopoietic stem cell transplantation. Vitamin D deficiency has been shown to be associated with increased risk of chronic GVHD in previous clinical studies. The purpose of this research is to investigate the effect of vitamin D supplementation in patients undergoing hematopoietic stem cell transplantation
Hematopoietic stem cell transplant candidates are randomized to vitamin D supplementation or usual care. Five milligrams (200,000 IU) of cholecalciferol is injected to intervention group before stem cell transplantation. Additional supplementation of cholecalciferol during follow-up period is determined according to the level of 25(OH)D3. The primary outcome is the incidence of chronic GVHD which is determined according to IBMTR criteria. The secondary outcome consists of the incidence of acute GVHD, incidence and severity of vitamin D deficiency, and serum concentration of 25(OH)D3. Study investigators expect that supplementation of vitamin D may improve the outcome of stem cell transplantation by reducing the incidence of chronic GVHD. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03483194 -
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03735992 -
Mind-body Medicine for Patients With Malignant Hematological Diseases
|
N/A | |
Recruiting |
NCT04959175 -
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04275154 -
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
|
||
Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00389428 -
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
|
Phase 1 | |
Completed |
NCT02193880 -
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
|
N/A | |
Recruiting |
NCT00071045 -
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
|
||
Not yet recruiting |
NCT05054231 -
Immunological Profile for Patients Treated With CAR-T Cells
|
N/A | |
Completed |
NCT02650791 -
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
|
Phase 3 | |
Completed |
NCT01362179 -
National Marrow Donor Program Long-Term Donor Follow-Up
|
||
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Terminated |
NCT03648372 -
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
|
Phase 1/Phase 2 | |
Recruiting |
NCT06422533 -
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients
|
N/A | |
Terminated |
NCT02895529 -
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
|
Phase 4 | |
Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT03083327 -
Prophylactic Early PN in HPT/BMT
|
N/A | |
Recruiting |
NCT03743480 -
Early Palliative Care and Hematological Cancer Patients
|
N/A | |
Completed |
NCT02635984 -
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
|
Phase 3 |